Abzena’s Post

NANEXA: Lining up to make Nanexa (close to) a pure GLP-1 play Following the focusing of the roadmap after the rights issue in October, Nanexa AB has now announced a further streamlining of its activities to extend runway into mid-2025, focusing on the projects most likely to generate near-term revenue and thus reduce need for further external financing. The three focus areas will be the own project NEX-22, the partner project with Novo Nordisk and other well advanced evaluation projects. This means NEX-20 is put on hold, along with NEX-18, until the financial situation allows. While this motivates a cut in our SOTP to 2.6-9.9 (4.3-11.6) SEK per share, due to the exclusion of NEX-20, we see this tactical reprioritization as another investor-friendly move to focus efforts on the most lucrative, assets in the portfolio. All in all, we continue to see with a wide range of possible outcomes for the company’s projects, all supporting a high potential relative to the current share price. Read the full report here: https://lnkd.in/dXgT-pXX #glp1 #t2d #obesitas #

📢 💊 I just registered for Asembia’s AXS25 Summit and look forward to an awesome conference next spring! I look forward to discussing the most comprehensive #specialtypharmacydatabase in the industry! #specialtypharmacy #pharmaceuticals #marketaccess #patientaccess #AMI #asembia25

What does the future of healthcare mean to you? DIA Europe 2024 is our opportunity to explore how, through collaboration and innovation, we can shape the future of pharmaceuticals together. Schedule a meeting with one of our Safety and Regulatory experts to learn how our dedicated technologies work to simplify the management and execution of your global safety and regulatory processes.https://bit.ly/3uLJgVM #DIAEurope24

🙋♀️ Hi all! Finally, back at a conference. I am looking forward seeing you all again. Lets discuss about the status and the future of #Art117 with #NotifiedBody #EMA #pharma and #medicaldevice industry. #combinedproducts #combinationproducts #MDR

Thoughts on this? >> ESMO24 Reflections on early-stage standouts and wipeouts >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #pharma #healthcare #competitivemarketing

🔍 Get up close and personal with the QX ONE Droplet Digital PCR System. This video tour of the platform highlights the key features and functions that make the QX ONE an optimal choice for biopharma and beyond. Watch the video to learn more about the QX ONE ddPCR System and workflow: https://ow.ly/O44l50R5bVJ #DropletDigitalPCR #Biopharma #QXONE

Thoughts on this? >> ESMO24 Reflections on early-stage standouts and wipeouts >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #competitivemarketing #pharma #pharmaceutical #biotech

Checking in from Lisbon, Portugal! Breakthrough Regulatory Day 1 brought us insightful conversations about the LifeSphere Regulatory roadmap, excitement around NavaX innovation, and customer insights about prioritizing #GenAI in workflows. To recap the day, AVP of Communications Morgan Waller Scott chatted with Chief Customer Officer Stephen Nuckols about today's highlights. Stay tuned for more on Day 2! #BTRegulatory #RegulatoryOperations #LifeSphere #PharmaTech #Bio #Regulatory

Speed to first-in-human studies for biologics requires the right expertise and technology to ensure successful development and manufacturing scale up. View this on-demand webinar introducing GPEx® Lightning: a fast, flexible & tailored process for generating highly stable & productive mammalian cell lines. https://ow.ly/ZqCq50QP0xJ